Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 2/20 | 0.48 |
| ▸ | BRD4 | O60885 | 3/20 | 0.47 |
| ▸ | APP | P05067 | 3/20 | 0.44 |
| ▸ | SNCA | P37840 | 3/20 | 0.44 |
| ▸ | LIPG | Q9Y5X9 | 5/20 | 0.44 |
| ▸ | LPL | P06858 | 4/20 | 0.44 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.42 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2240402 | 0.90 | APP (0.44) | HTR6BRD4APPSNCALIPG | |
| SCHEMBL17052505 | 0.89 | IRAK4 (0.41) | HTR6BRD4LIPGLPLIRAK4 | |
| SCHEMBL14764906 | 0.84 | KCNQ3 (0.42) | HTR6BRD4LIPGLPLIRAK4 | |
| SCHEMBL12260754 | 0.84 | HTR6 (0.55) | HTR6LIPGLPL | |
| SCHEMBL8250873 | 0.83 | BRD4 (0.42) | BRD4SNCALIPGLPLIRAK4 | |
| SCHEMBL18230142 | 0.82 | IRAK4 (0.43) | LIPGLPLIRAK4 | |
| SCHEMBL18239698 | 0.80 | LPL (0.44) | LIPGLPLIRAK4 | |
| SCHEMBL3288256 | 0.79 | MAPK14 (0.47) | LIPGLPL | |
| SCHEMBL17149343 | 0.79 | HDAC8 (0.46) | HTR6LIPGLPLIRAK4 | |
| SCHEMBL15333687 | 0.78 | CYP11B1 (0.52) | BRD4LIPGLPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180148429-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES | SELVITA S.A. (PL) | 2018-05-31 | — | — | US | disclosed |
| US-20180148429-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES | SELVITA S.A. (PL) | 2018-05-31 | — | — | US | disclosed |
| US-20180148429-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES | SELVITA S.A. (PL) | 2018-05-31 | — | — | US | disclosed |
| WO-2016180536-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES | SELVITA S.A. (PL) | 2016-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148429-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES | BRCA1, NQO2, NQO1 | HTR6 2563/4885BRD4 127/4885APP 4554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.